Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics
Spero Therapeutics, Inc. (SPRO)
Today's Latest Price: $17.28 USD
Updated Dec 2 4:00pm
Add SPRO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
SPRO Stock Summary
- SPRO's went public 3.08 years ago, making it older than merely 9.84% of listed US stocks we're tracking.
- Of note is the ratio of Spero Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 9.08% of US stocks have a lower such ratio.
- SPRO's price/sales ratio is 41.77; that's higher than the P/S ratio of 94.85% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Spero Therapeutics Inc are AFMD, CDTX, GRTS, VIR, and CBIO.
- Visit SPRO's SEC page to see the company's official filings. To visit the company's web site, go to sperotherapeutics.com.
SPRO Stock Price Chart Interactive Chart >
SPRO Price/Volume Stats
| Current price | $17.28 | 52-week high | $17.85 |
| Prev. close | $16.98 | 52-week low | $5.25 |
| Day low | $16.78 | Volume | 198,900 |
| Day high | $17.85 | Avg. volume | 208,879 |
| 50-day MA | $13.56 | Dividend yield | N/A |
| 200-day MA | $11.59 | Market Cap | 469.79M |
Spero Therapeutics, Inc. (SPRO) Company Bio
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Loading social stream, please wait...